Secondary hematological malignancies after breast cancer chemotherapy

According to several reports, the 10 year incidence of secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after systemic chemotherapy is approximately 1.5%. The cumulative risk increases by 0.25--1% for the first 8 years after treatment. We have reported only 6 cases of hem...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2005-08, Vol.46 (8), p.1183-1188
Main Authors: Park, Myung Joon, Park, Yeon Hee, Ahn, Heui June, Choi, Won, Paik, Kwang Hyun, Kim, Jung Min, Chang, Yoon Hwan, Ryoo, Baek-Yeol, Yang, Sung Hyun
Format: Article
Language:English
Subjects:
AML
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - surgery
Carcinoma, Ductal, Breast - drug therapy
Carcinoma, Ductal, Breast - surgery
Chemotherapy, Adjuvant - adverse effects
Chemotherapy, Adjuvant - methods
Disease Progression
Dose-Response Relationship, Drug
Fatal Outcome
Female
Follow-Up Studies
Hematologic Neoplasms - chemically induced
Hematologic Neoplasms - diagnosis
Hematologic Neoplasms - drug therapy
Humans
lymphoma
Lymphoma - chemically induced
Lymphoma - diagnosis
Lymphoma - drug therapy
MDS
Middle Aged
Neoplasms, Second Primary - chemically induced
Neoplasms, Second Primary - diagnosis
Neoplasms, Second Primary - drug therapy
secondary hematological malignancies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to several reports, the 10 year incidence of secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after systemic chemotherapy is approximately 1.5%. The cumulative risk increases by 0.25--1% for the first 8 years after treatment. We have reported only 6 cases of hematological malignancies (0.3%) after breast cancer chemotherapy in our institute. We detected 2 cases of secondary AML and 1 case of MDS, 19, 52 and 12 months, respectively, after systemic chemotherapy for breast cancer. Published data on the occurrence of secondary hematological malignancies other than AML or MDS in this setting are scarce. We encountered diffuse large B-cell lymphoma, angioimmunoblastic lymphoma and mantle cell lymphoma as secondary hematological malignancies after systemic chemotherapy for breast cancer.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190500125705